NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novavax Inc (NVAX) does not present a compelling buy opportunity for a beginner, long-term investor at this time. The stock lacks strong positive catalysts, has neutral insider and hedge fund sentiment, and no recent significant news. Additionally, technical indicators show no clear upward momentum, and proprietary trading signals do not suggest a strong buy. While analysts have slightly raised price targets, the stock's overall trend and lack of financial data make it a hold for now.
The MACD histogram is negative (-0.0785) and contracting, indicating weak momentum. RSI is neutral at 45.463, and moving averages are converging, suggesting no clear trend. Key support is at 8.49, and resistance is at 9.85. The stock is trading near its pivot point of 9.17, showing indecision in the market.
Analyst upgrades with slightly higher price targets and a potential differentiated tolerability profile for Nuvaxovid compared to mRNA vaccines.
No recent news, neutral sentiment from hedge funds and insiders, lack of financial performance data, and no recent congress trading activity. The stock also shows a potential for negative returns in the next month (-2.14%).
No financial data available for the latest quarter.
Analysts have slightly raised price targets, with TD Cowen increasing it to $9 and B. Riley raising it to $18. However, the consensus remains mixed, with one analyst maintaining a Hold rating and another a Buy.
